Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00606437 | Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants | completed | Phase 1 | 40 | Duke UniversityOTHER | 1 | May 16, 2014 | clinicaltrials |
| NCT00743288 | Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | OncotherapeuticsINDUSTRY | 1 | May 8, 2014 | clinicaltrials |
| NCT00933985 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia |
| terminated |
| Phase 1 |
| 22 |
| National Cancer Institute (NCI)NIH |
| 2 |
| May 1, 2014 |
| clinicaltrials |
| NCT01231919 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 2 | Apr 29, 2014 | clinicaltrials |
| NCT01161511 | Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | completed | Phase 1 | 27 | Xencor, Inc.INDUSTRY | 1 | Apr 21, 2014 | clinicaltrials |
| NCT00482846 | Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma | completed | Phase 1 | 38 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 15, 2014 | clinicaltrials |
| NCT01105247 | Safety of PCI-32765 in Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 133 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 31, 2014 | clinicaltrials |
| NCT02007811 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination(B-cell therapy) | unknown | Phase 1 / Phase 2 | 15 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00943293 | Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies | terminated | Phase 1 | 1 | University of ChicagoOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT02081937 | CART-19 Immunotherapy in Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 2 | Chinese PLA General HospitalOTHER | 1 | Mar 11, 2014 | clinicaltrials |
| NCT00791011 | Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | completed | Phase 1 | 33 | AmgenINDUSTRY | 0 | Mar 5, 2014 | clinicaltrials |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00499811 | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00458731 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | completed | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2014 | clinicaltrials |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 3 | Feb 4, 2014 | clinicaltrials |
| NCT01022255 | Autologous Vaccine for Follicular Lymphoma | completed | Phase 1 | 28 | Icon Genetics GmbHINDUSTRY | 1 | Jan 30, 2014 | clinicaltrials |
| NCT00725634 | A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma(P05538) | completed | Phase 1 | 41 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 27, 2014 | clinicaltrials |
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 58 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2014 | clinicaltrials |
| NCT00590603 | Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma(AAV) | terminated | Phase 1 | 25 | Duke UniversityOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00769288 | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2014 | clinicaltrials |
| NCT00019708 | Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00985959 | A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT) | completed | Phase 1 | 101 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Dec 2, 2013 | clinicaltrials |
| NCT00361088 | A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00722488 | Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma | completed | Phase 1 | 56 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00483262 | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2013 | clinicaltrials |
| NCT01205737 | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects | completed | Phase 1 | 186 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 10 | Oct 22, 2013 | clinicaltrials |
| NCT00243035 | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00068315 | Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00079378 | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 84 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00293345 | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00398515 | Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00547365 | Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction | completed | Phase 1 / Phase 2 | 10 | University of TennesseeOTHER | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00807872 | Radioimmunoimaging of AL Amyloidosis | completed | Phase 1 | 40 | University of TennesseeOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT01815086 | Radioimmunoimaging of Light Chain (AL) Amyloidosis | completed | Phase 1 | 30 | University of TennesseeOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT00947388 | Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 1 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2013 | clinicaltrials |
| NCT01232712 | A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies | completed | Phase 1 / Phase 2 | 15 | Vaxil Therapeutics Ltd.INDUSTRY | 1 | Aug 9, 2013 | clinicaltrials |
| NCT01118689 | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | completed | Phase 1 | 39 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00507442 | Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients(EVOLUTION) | completed | Phase 1 / Phase 2 | 158 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 26, 2013 | clinicaltrials |
| NCT00723359 | Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 32 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00871702 | Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease | completed | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT01371227 | A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 3 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Jul 4, 2013 | clinicaltrials |
| NCT00377104 | Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00994500 | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00609817 | Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma | terminated | Phase 1 | 9 | La Jolla Pharmaceutical CompanyINDUSTRY | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00776802 | GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(GCS-100LE) | withdrawn | Phase 1 / Phase 2 | 0 | La Jolla Pharmaceutical CompanyINDUSTRY | 1 | Jun 25, 2013 | clinicaltrials |
| NCT01149668 | A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer | completed | Phase 1 | 7 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00010192 | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
Data updated 23 days agoSource updated May 16, 2014source: clinicaltrials